GSK Nears Key Hepatitis B Milestone With Completion of B-Well 1 Phase 3 Trial

GlaxoSmithKline (GSK) announced an update on their ongoing clinical study.

GSK’s latest hepatitis B update centers on its Phase 3 trial “Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B Virus (B-Well 1).” The goal is to show that bepirovirsen can safely cut virus levels and keep them low versus placebo, a key step toward a potential functional cure.

The study tests bepirovirsen, an injected drug designed to lower hepatitis B surface antigen in people already on long term oral antivirals. It is compared against a matching placebo, with both groups continuing background nucleos(t)ide analogue therapy that reflects current standard of care.

This is an interventional Phase 3 trial with patients randomly assigned to bepirovirsen or placebo. It uses a parallel group design and a double blind setup where patients, doctors, and study staff do not know who gets active drug, aiming to fairly test treatment benefit and risk.

The study runs in four stages over about two years per patient, including 24 weeks of blinded bepirovirsen or placebo plus further follow up on and off background oral treatment. This structure lets GSK track both short term response and how durable virus control might be after treatment changes.

The trial was first submitted on Nov. 21, 2022, marking the formal start of regulatory tracking and signaling GSK’s push to move bepirovirsen into late-stage testing. The latest update on May 15, 2026, confirms status as completed, which is a key milestone before data can be fully analyzed and later shared.

A completed Phase 3 study in chronic hepatitis B positions GSK for a possible new growth driver if results are strong, as investors tend to reward credible late-stage assets in large unmet markets. At the same time, the absence of posted results keeps outcome risk on the table, which can cap near term upside for GSK stock.

Competitors like Janssen and other large pharma groups also pursue functional cure strategies in hepatitis B, so investor focus will be on how bepirovirsen data compare on efficacy, safety, and durability. A clearly differentiated profile could strengthen GSK’s negotiating power with payers and drive higher long term cash flows.

For now, the key takeaway is that B-Well 1 has finished patient participation and awaits full data readout, an inflection point that can swing sentiment sharply in either direction. The study is completed with recent updates logged, and further details will be available on the ClinicalTrials portal.

To learn more about GSK’s potential, visit the GlaxoSmithKline drug pipeline page.